Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)

NCT03040791 is registered in ClinicalTrials.gov with Hospital Moinhos de Vento as lead sponsor.

NCT NCT03040791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03040791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)
Lead sponsor
Hospital Moinhos de Vento
Phase
Phase 2
Overall status
Unknown status
Start date
June 1, 2018
Completion date
March 1, 2022
Enrollment
38 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer